ES2103832T3 - Derivados de 2-fenil y 2-tienil-(2)-piperidina que tienen propiedades neuroprotectoras. - Google Patents

Derivados de 2-fenil y 2-tienil-(2)-piperidina que tienen propiedades neuroprotectoras.

Info

Publication number
ES2103832T3
ES2103832T3 ES91920369T ES91920369T ES2103832T3 ES 2103832 T3 ES2103832 T3 ES 2103832T3 ES 91920369 T ES91920369 T ES 91920369T ES 91920369 T ES91920369 T ES 91920369T ES 2103832 T3 ES2103832 T3 ES 2103832T3
Authority
ES
Spain
Prior art keywords
tienyl
neuroprotecting
piperidine
phenyl
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91920369T
Other languages
English (en)
Inventor
Ronald Conrad Griffith
Richard John Schmiesing
Robert John Murray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Astra AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra AB filed Critical Astra AB
Application granted granted Critical
Publication of ES2103832T3 publication Critical patent/ES2103832T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/12—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with only hydrogen atoms attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

COMPUESTOS DE LA FORMULA (I) EN DONDE R1 Y R2, QUE PUEDEN SER IGUALES O DIFERENTE, REPRESENTAN HIDROGENO O C1-6 ALQUIL, R3 Y R4 DE FORMA INDEPENDIENTE REPRESENTAN UNO O MULTIPLES RADICALES SELECCIONADOS DE HIDROGENO, HALOGENO, NH2, NO2, HALOGENO, HIDROXIL, C1-6 ALCOXI O C1-6 ALQUIL, X REPRESENTA S O UN GRUPO CH = CH -, Y LOS DERIVADOS ADMISIBLES FARMACEUTICAMENTE A PARTIR DE ESTOS COMPUESTOS QUE SON UTILIZADOS COMO PRODUCTOS FARMACEUTICOS, EN PARTICULAR LOS QUE POSEEN N ARTATO (NMDA) DISPONIENDO DE PROPIEDADES DE BLOQUEO Y SIENDO UTILIZADOS EN EL TRATAMIENTO Y/O PREVENCION DE DESORDENES NEUROLOGICOS.
ES91920369T 1990-10-15 1991-10-11 Derivados de 2-fenil y 2-tienil-(2)-piperidina que tienen propiedades neuroprotectoras. Expired - Lifetime ES2103832T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59714790A 1990-10-15 1990-10-15

Publications (1)

Publication Number Publication Date
ES2103832T3 true ES2103832T3 (es) 1997-10-01

Family

ID=24390300

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91920369T Expired - Lifetime ES2103832T3 (es) 1990-10-15 1991-10-11 Derivados de 2-fenil y 2-tienil-(2)-piperidina que tienen propiedades neuroprotectoras.

Country Status (11)

Country Link
US (1) US5714500A (es)
EP (1) EP0553278B1 (es)
JP (1) JP3094450B2 (es)
AT (1) ATE154010T1 (es)
DE (1) DE69126438T2 (es)
DK (1) DK0553278T3 (es)
ES (1) ES2103832T3 (es)
GR (1) GR3024388T3 (es)
IE (1) IE913606A1 (es)
PT (1) PT99207B (es)
WO (1) WO1992006957A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW281670B (es) * 1993-09-02 1996-07-21 Hoffmann La Roche
US5563157B1 (en) * 1994-10-31 1999-02-02 Hoecst Marion Roussel Inc Heterocycle substituted propenoic acid derivatives and pharmaceutical compositions thereof
EP1436258A4 (en) * 2001-03-08 2005-03-23 Univ Emory ANTAGONISTS OF THE NMDA RECEPTOR DEPENDENT OF PH
EA201070077A1 (ru) * 2007-06-29 2010-08-30 Эмори Юниверсити Антагонисты nmda-рецепторов с нейропротективным действием

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2524643A (en) * 1947-12-04 1950-10-03 Maltbie Lab Inc 3-phenyl-2-piperidones
US2636881A (en) * 1951-01-06 1953-04-28 Sharp & Dohme Inc 3-substituted, 3-aryl, 2-pipecolines and salts thereof
EP0317953A3 (en) * 1987-11-24 1990-12-05 G.D. Searle & Co. N-(1-thienylcycloalkyl)alkenylamines for treatment of neurotoxic injury
EP0346791B1 (en) * 1988-06-14 1994-04-06 G.D. Searle & Co. 1,2-diarylethylamines for treatment of neurotoxic injury
US4924008A (en) * 1989-05-04 1990-05-08 American Home Products Corporation Benzobicycloalkane derivatives as anticonvulsant neuroprotective agents
US5109017A (en) * 1990-09-26 1992-04-28 Fisons Corporation (2-thienyl)alkylamine derivatives having neuroprotective properties

Also Published As

Publication number Publication date
EP0553278B1 (en) 1997-06-04
ATE154010T1 (de) 1997-06-15
DE69126438D1 (de) 1997-07-10
EP0553278A1 (en) 1993-08-04
IE913606A1 (en) 1992-04-22
JPH06501701A (ja) 1994-02-24
PT99207B (pt) 1999-04-30
DE69126438T2 (de) 1997-10-02
GR3024388T3 (en) 1997-11-28
WO1992006957A1 (en) 1992-04-30
US5714500A (en) 1998-02-03
PT99207A (pt) 1992-09-30
DK0553278T3 (da) 1997-08-25
JP3094450B2 (ja) 2000-10-03

Similar Documents

Publication Publication Date Title
ES2114952T3 (es) Agentes antianginales derivados de quinazolinona.
TW347387B (en) Piperidine derivatives
ATE188472T1 (de) 4-arylmethyloxymethyl piperidine als tachykinin antagonisten
DK0646115T3 (da) Heterocykliske/cykliske aminderivater
DK0677046T3 (da) Piperazinderivater som 5-HT-antagonister.
DE69203911D1 (de) Antihistaminische und nicht sedierende Benzimidazolderivate, Verfahren zu deren Herstellung und deren Anwendung als Arzneimittel.
DE69107064T2 (de) Indolderivate.
ES2103832T3 (es) Derivados de 2-fenil y 2-tienil-(2)-piperidina que tienen propiedades neuroprotectoras.
ATE95816T1 (de) 2-((4-piperidinyl)methyl>-1,2,3,4tetrahydroisochinolin-derivate, ihre herstellung und ihre therapeutische verwendung.
ATE70837T1 (de) Allylmercaptoacetyl-sydnonimine, verfahren zu ihrer herstellung und ihre verwendung.
ATE225335T1 (de) Amide derivate als 5-ht1a liganden
DK0777653T3 (da) Dihydropyridinderivater som bradykininantagonister
DE69330601D1 (de) Serotoninergische ergolin derivate
ATE80881T1 (de) Heteroarotinoid-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen.
NZ225528A (en) Benzimidazoles substituted in the 2 position by n(4-n-guanidyl) piperidinyl radicals; preparations thereof; pharmaceutical compositions
DE69725167D1 (de) N-benzolsulfonyl-l-prolin derivate, verfahren zu ihrer herstellung und ihre therapeutische verwendung
KR970706280A (ko) 5-HT1A 길항제로서의 비사이클릭 카복스아미드(Bicyclic carboxamides as 5-HT1 antagonists)
ATE168681T1 (de) 3-phenylureido-1,5-benzodiazepin-dione verwendbar als gastrin- oder cck antagonisten
ATE63309T1 (de) 2,3-dihydro-2-oxo-3-benzofuranylessigs|urederivate und diese enthaltende arzneimittel.
DE69104364T2 (de) Verfahren zur herstellung von streptograminderivaten.
DE69403896T2 (de) 4-amino-2-(hetero)aryl-butanamide verwenbar als 5-ht1a-antagonisten
HUP0402149A2 (hu) Vízoldható fenil-piridazin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
DK0544748T3 (da) Spiro cycloalkylbenzen-1, 1-(1,2,3,4-tetrahydroisoquinoliner) med neurobeskyttende egenskaber
KR930000501A (ko) 피리디닐피페라진 유도체

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 553278

Country of ref document: ES